GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fuse Medical Inc (OTCPK:FZMD) » Definitions » ROE %

Fuse Medical (Fuse Medical) ROE % : Negative Equity% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Fuse Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Fuse Medical's annualized net income for the quarter that ended in Jun. 2023 was $1.23 Mil. Fuse Medical's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $-0.39 Mil. Therefore, Fuse Medical's annualized ROE % for the quarter that ended in Jun. 2023 was Negative Equity%.

The historical rank and industry rank for Fuse Medical's ROE % or its related term are showing as below:

FZMD' s ROE % Range Over the Past 10 Years
Min: -2706.94   Med: 55.19   Max: Negative Equity
Current: Negative Equity

During the past 13 years, Fuse Medical's highest ROE % was Negative Equity%. The lowest was -2,706.94%. And the median was 55.19%.

FZMD's ROE % is ranked better than
99.88% of 804 companies
in the Medical Devices & Instruments industry
Industry Median: -0.68 vs FZMD: Negative Equity

Fuse Medical ROE % Historical Data

The historical data trend for Fuse Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fuse Medical ROE % Chart

Fuse Medical Annual Data
Trend Aug13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Equity -2,706.94 - - Negative Equity

Fuse Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - Negative Equity - Negative Equity

Competitive Comparison of Fuse Medical's ROE %

For the Medical Devices subindustry, Fuse Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuse Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fuse Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Fuse Medical's ROE % falls into.



Fuse Medical ROE % Calculation

Fuse Medical's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=3.098/( (-3.432+-0.311)/ 2 )
=3.098/-1.8715
=Negative Equity %

Fuse Medical's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=1.232/( (-0.539+-0.232)/ 2 )
=1.232/-0.3855
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Fuse Medical  (OTCPK:FZMD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=1.232/-0.3855
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1.232 / 19.988)*(19.988 / 18.8755)*(18.8755 / -0.3855)
=Net Margin %*Asset Turnover*Equity Multiplier
=6.16 %*1.0589*N/A
=ROA %*Equity Multiplier
=6.52 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=1.232/-0.3855
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (1.232 / 1.26) * (1.26 / 1.476) * (1.476 / 19.988) * (19.988 / 18.8755) * (18.8755 / -0.3855)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9778 * 0.8537 * 7.38 % * 1.0589 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Fuse Medical ROE % Related Terms

Thank you for viewing the detailed overview of Fuse Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fuse Medical (Fuse Medical) Business Description

Traded in Other Exchanges
N/A
Address
1565 N. Central Expressway, Suite 220, Richardson, TX, USA, 75080
Fuse Medical Inc is a manufacturer and distributor of medical devices. The company provides a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as degenerative and deformity spine, orthobiologics, and regenerative medicine.
Executives
Lawrence Scott Yellin director, officer: Chief Financial Officer 5081 PINEVIEW CIRCLE, DELRAY BEACH FL 33445
Christopher C Reeg director, 10 percent owner, officer: Chief Executive Officer 3024 WESTMINSTER AVE, DALLAS TX 75205
Reeg Medical Industries, Inc. 10 percent owner 3024 WESTMINSTER AVE., DALLAS TX 75205
Mark W Brooks 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Bosita Renato V. Jr. director TEXAS BACK INSTITUTE, 6020 WEST PARKER ROAD #200, PLANO TX 75025
Kalra Ricky Raj S. director 2513 SUNTREE LANE, PLANO TX 75025
Nc 143 Family Holdings, Lp 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Medtech Family Trust 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Mclaughlin William E Iii director 1565 NORTH CENTRAL EXPRESSWAY, 2ND FLOOR, RICHARDSON TX 75080
Nc 143 Family Holdings Gp Llc 10 percent owner 1565 NORTH CENTRAL EXPRESSWAY, SUITE 200, RICHARDSON TX 75080
Chris Pratt director, 10 percent owner, officer: Chief Medical Officer 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
Randall Dei director, officer: Medical Director of Podiatry 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
Rusty Shelton director, 10 percent owner, officer: Chief Development Officer 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
David Hexter director, officer: Interim CFO 4770 BRYANT IRVIN COURT, SUITE 300, FORT WORTH TX 76107
D Alan Meeker director, 10 percent owner, officer: Chief Executive Officer 4770 BRYANT IRVIN COURT, SUITE 400, FORT WORTH TX 76107

Fuse Medical (Fuse Medical) Headlines

From GuruFocus